Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After poliomyelitis has been eradicated, access to live polioviruses will be highly restricted and the use of oral poliovirus vaccine (OPV) will probably be discontinued. Countries using OPV must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because data on the immunogenicity of IPV in tropical developing countries are limited, we conducted a randomized, controlled trial of IPV in Cuba. METHODS: The study population consisted of healthy infants born in Havana. A total of 166 infants were randomly assigned to two groups. Group A received a combination of the diphtheria-pertussis-tetanus (DPT) vaccine, the Haemophilus influenzae type b (Hib) vaccine, and IPV (DPT-Hib-IPV) at 6, 10, and 14 weeks of age. Group B, the control group, received a combination of the DPT vaccine and the Hib vaccine at 6, 10, and 14 weeks of age. Another group (group C, 100 infants), which did not undergo randomization at the same time as groups A and B, received the DPT-Hib-IPV combination at 8 and 16 weeks of age. Serum samples were collected before vaccination and at least 4 weeks after the last dose. Stool samples were obtained before and 7 days after challenge with OPV. RESULTS: The seroconversion rates in group A were 94%, 83%, and 100% for types 1, 2, and 3 poliovirus, respectively. There were no seroconversions in group B. The seroconversion rates in group C were 90%, 89%, and 90% for poliovirus types 1, 2, and 3, respectively. For groups A, B, and C, the virus isolation rates after challenge with OPV were 94%, 91%, and 97%, respectively, and the mean log10 viral titers of any serotype were 3.46, 3.89, and 3.37, respectively. There was one major adverse event, an episode of hypotonia. CONCLUSIONS: Vaccination with two or three doses of IPV resulted in a rate of seroconversion of at least 90%, except for seroconversion against type 2. The viral titer of OPV shed in the stool after OPV challenge was reduced in both groups receiving IPV. (ClinicalTrials.gov number, NCT00260312 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown that IPV reduces the duration and rate of virus shedding in immunised individuals compared with unimmunised individuals, although IPV is not effective in preventing PV replication in the gut [69,70].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [69]
Citations
Cites
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Cody, C. L., Baraff, L. J., Cherry, J. D., Marcy, S. M., & Manclark, C. R. (1981) · Pediatrics · doi:10.1542/peds.68.5.650 · Cited by 536
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Circulation of type 1 vaccine-derived poliovirus in the philippines in 2001
Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13512-13521.2004 · Cited by 146
Recombinant Vaccine–Derived Poliovirus in Madagascar
Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclère, P., & Delpeyroux, F. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0907.020692 · Cited by 138
Inactivated poliovirus vaccine: Past and present experience
Murdin, A. D., Barreto, L., & Plotkin, S. (1996) · Vaccine · doi:10.1016/0264-410x(95)00211-i · Cited by 135
Efficacy of inactivated poliovirus vaccine in India.
Krishnan, R., Jadhav, M., & John, T. J. (1983) · Europe PMC (PubMed Central) · Cited by 122
Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba
Lago, P. M., Gary, H. E., Pérez, L. S., Cáceres, V., Olivera, J. B., Puentes, R. P., Corredor, M. B., Jímenez, P., Pallansch, M. A., & Cruz, R. G. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg185 · Cited by 117
Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J. (1966) · Journal of Hygiene · doi:10.1017/s0022172400040389 · Cited by 101
Trial of a Supplemental Dose of Four Poliovirus Vaccines
Sutter, R. W., Suleiman, A. J. M., Malankar, P., Al-Khusaiby, S., Mehta, F., Clements, G. B., Pallansch, M. A., & Robertson, S. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431103 · Cited by 84
Research works printed but not linked: 11
- 2004, Wkly Epidemiol Rec, 79, 349
- 2004, Wkly Epidemiol Rec, 79, 401
- Sutter RW, 2004, Bull World Health Organ, 82, 31
- 2003, Wkly Epidemiol Rec, 78, 241
- 1996, Bull World Health Organ, 74, 253
- Mas Lago P, 1999, Bull World Health Organ, 77, 681
- Kok PW, 1992, Bull World Health Organ, 70, 93
- Krishnan R, 1983, Bull World Health Organ, 61, 689
- Simoes EA, 1985, Am J Dis Child, 139, 977
- Ghendon YUZ, 1961, Acta Virol, 5, 265
- Marine WM, 1962, Am J Hyg, 76, 173
Cited by
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221
Austin, P. C., Manca, A., Zwarenstein, M., Juurlink, D. N., & Stanbrook, M. B. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.002 · Cited by 159
Resik, S., Tejeda, A., Lago, P. M., Diaz, M., Carmenates, A., Sarmiento, L., Alemañi, N., Galindo, B., Burton, A., Friede, M., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651611 · Cited by 146
“In contrast to other trials, we can rule out the following potential causes for the low immunogenicity: (1) variation in intradermal administration, because all doses were administered in a standardized approach using a needle-free device; (2) low immunogenicity of IPV [46], because the seroconversion rates after intr…”
BackgroundResultEfficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112
Expert Review on Poliovirus Immunity and Transmission
Duintjer Tebbens, R. J., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., Patriarca, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01864.x · Cited by 109
Anand, A., Zaman, K., Estívariz, C. F., Yunus, M., Gary, H. E., Weldon, W. C., Bari, T. I., Steven Oberste, M., Wassilak, S. G., Luby, S. P., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.039 · Cited by 105
Agnandji, S. T., Asante, K. P., Lyimo, J., Vekemans, J., Soulanoudjingar, S. S., Owusu, R., Shomari, M., Leach, A., Fernandes, J., Dosoo, D., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/656190 · Cited by 73
Poliovirus Vaccine–Inactivated
Vidor, E. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00047-x · Cited by 93
Vaccination against polio should not be stopped
Chumakov, K., Ehrenfeld, E., Wimmer, E., & Agol, V. I. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1769 · Cited by 85
Pliaka, V., Kyriakopoulou, Z., & Markoulatos, P. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.28 · Cited by 85
Mucosal Immunity after Vaccination with Monovalent and Trivalent Oral Poliovirus Vaccine in India
Grassly, N. C., Jafari, H., Bahl, S., Durrani, S., Wenger, J., Sutter, R. W., & Aylward, R. B. (2009) · The Journal of Infectious Diseases · doi:10.1086/605330 · Cited by 77
Tebbens, R. J. D., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., PATRIARCA, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/risa.12031 · Cited by 75
Poliovirus vaccine—inactivated
Vidor, E. J., & Plotkin, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00034-3 · Cited by 80
Polio endgame: the global introduction of inactivated polio vaccine
Patel, M. M., Zipursky, S., Orenstein, W., Garon, J. R., & Zaffran, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001750 · Cited by 77
Waning Intestinal Immunity After Vaccination With Oral Poliovirus Vaccines in India
Grassly, N. C., Jafari, H., Bahl, S., Sethi, R., Deshpande, J. M., Wolff, C., Sutter, R. W., & Aylward, R. B. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis241 · Cited by 72
Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses
Thompson, K. M., Pallansch, M. A., Tebbens, R. J. D., Wassilak, S. G. F., & Cochi, S. L. (2012) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01891.x · Cited by 70
Parker, E. P. K., Molodecky, N. A., Pons-Salort, M., O’Reilly, K. M., & Grassly, N. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1052800 · Cited by 75
Poliovirus vaccination options for achieving eradication and securing the endgame
Estívariz, C. F., Pallansch, M. A., Anand, A., Wassilak, S. G., Sutter, R. W., Wenger, J. D., & Orenstein, W. A. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.007 · Cited by 66
A case for developing antiviral drugs against polio
Collett, M. S., Neyts, J. H., & Modlin, J. F. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.04.002 · Cited by 69
Poliovirus vaccine-inactivated
Plotkin, S. A., & Vidor, E. J. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50029-5 · Cited by 70
Wright, P. F., Connor, R. I., Wieland‐Alter, W., Hoen, A. G., Boesch, A. W., Ackerman, M. E., Oberste, M. S., Gast, C., Brickley, E. B., Asturias, E. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30169-4 · Cited by 63
Dowdle, W., Van Der Avoort, H., De Gourville, E., Delpeyroux, F., Desphande, J., Hovi, T., Martin, J., Pallansch, M., Kew, O., & Wolff, C. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00844.x · Cited by 61
“7.(1,59,60,69,85,189) The mean differs by nearly a log from the mean WPV titer of 104.”
BackgroundSutter, R. W., Bahl, S. K., Deshpande, J. M., Verma, H., Ahmad, M., Venugopal, P., Rao, J. V., Agarkhedkar, S., Lalwani, S. K., Kunwar, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00237-8 · Cited by 61
World wide experience with inactivated poliovirus vaccine
Bonnet, M.-C., & Dutta, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.07.026 · Cited by 68
Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control
Thompson, K. M., Pallansch, M. A., Tebbens, R. J. D., Wassilak, S. G. F., Kim, J., & Cochi, S. L. (2013) · Risk Analysis · doi:10.1111/risa.12019 · Cited by 59
Thompson, K. M., & Tebbens, R. J. D. (2008) · PubMed Central · Cited by 56
Intestinal Immunity Is a Determinant of Clearance of Poliovirus After Oral Vaccination
Wright, P. F., Wieland‐Alter, W., Ilyushina, N. A., Hoen, A. G., Arita, M., Boesch, A. W., Ackerman, M. E., van der Avoort, H., Oberste, M. S., Pallansch, M. A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit671 · Cited by 57
Duintjer Tebbens, R. J., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit838 · Cited by 48
The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox
Heinsbroek, E., & Ruitenberg, E. J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.095 · Cited by 55
Sáez‐Llorens, X., Clemens, R. L., Leroux-Roels, G. G., Jimeno, J., Clemens, S. A. C., Weldon, W. C., Oberste, M. S., Molina, N., & Bandyopadhyay, A. S. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00488-0 · Cited by 45
Mucosal immunity and poliovirus vaccines: Impact on wild poliovirus infection and transmission
Okayasu, H., Sutter, R. W., Czerkinsky, C. C., & Ogra, P. L. O. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.059 · Cited by 47
Immunisation against poliomyelitis: moving forward
Ehrenfeld, E., Glass, R. I., Agol, V. I., Chumakov, K., Dowdle, W. R., John, T. J., Katz, S. L., Miller, M. D., Breman, J. G., Modlin, J. F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60597-8 · Cited by 44
Brickley, E. B., Strauch, C. B., Wieland‐Alter, W., Connor, R. I., Lin, S., Weiner, J. A., Ackerman, M. E., Arita, M., Oberste, M. S., Weldon, W. C., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix556 · Cited by 41
“Moreover, a 2001 trial in a Sabin virus–free Cuban population found that the percentage of infants who shed any type of poliovirus after tOPV challenge was >90% regardless of whether the infants had received zero, 2, or 3 prior doses of IPV [25].”
BackgroundSequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
Ciapponi, A., Bardach, A., Ares, L. R., Glujovsky, D., Cafferata, M. L., Cesaroni, S., & Aikant, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011260.pub2 · Cited by 45
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
Dietrich, J., Andreasen, L. V., Andersen, P. L., & Agger, E. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100879 · Cited by 40
Snider, C. J., Zaman, K., Estivariz, C. F., Yunus, M., Weldon, W. C., Wannemuehler, K. A., Oberste, M. S., Pallansch, M. A., Wassilak, S. G., Bari, T. I. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30503-3 · Cited by 38
Verdijk, P., Rots, N. Y., & Bakker, W. A. M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.51 · Cited by 37
Assessing the stability of polio eradication after the withdrawal of oral polio vaccine
Famulare, M., Selinger, C., McCarthy, K. A., Eckhoff, P. A., & Chabot‐Couture, G. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002468 · Cited by 41
Tebbens, R. J. D., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1114-6 · Cited by 36
Saleem, A. F., Mach, O., Yousafzai, M. T., Khan, A., Weldon, W. C., Oberste, M. S., Zaidi, S. S. Z., Alam, M. M., Quadri, F., Sutter, R. W., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix577 · Cited by 35
Bandyopadhyay, A. S., Modlin, J. F., Wenger, J., & Gast, C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy633 · Cited by 31
Tebbens, R. J. D., Hampton, L. M., Wassilak, S. G. F., Pallansch, M. A., Cochi, S. L., & Thompson, K. M. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000340 · Cited by 32
The Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
“Several studies have shown that IPV reduces the duration and rate of virus shedding in immunised individuals compared with unimmunised individuals, although IPV is not effective in preventing PV replication in the gut [69,70].”
BackgroundUse of inactivated poliovirus vaccine for poliovirus outbreak response
Bandyopadhyay, A. S., Cavestany, R. L., Blake, I. M., Macklin, G., Cooper, L., Grassly, N. C., Nery, A. L. M. D. S., & Mach, O. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00505-4 · Cited by 29
Kalkowska, D. A., Tebbens, R. J. D., & Thompson, K. M. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr399 · Cited by 29
Mangal, T. D., Aylward, R. B., & Grassly, N. C. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt203 · Cited by 28
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance
Sutter, R. W., Eisenhawer, M., Molodecky, N. A., Verma, H., & Okayasu, H. (2024) · Pathogens · doi:10.3390/pathogens13030224 · Cited by 30
“The shorter excretion period was confirmed in Sweden [22] and the decrease in excreted titer in IPV-vaccinated following a tOPV challenge in Cuba [23].”
BackgroundBrickley, E. B., Wieland‐Alter, W., Connor, R. I., Ackerman, M. E., Boesch, A. W., Arita, M., Weldon, W. C., O’Ryan, M., Bandyopadhyay, A. S., & Wright, P. F. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy603 · Cited by 26
Tebbens, R. J. D., Pallansch, M. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130123 · Cited by 25
Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine
Gamage, D. G., Mach, O., Palihawadana, P., Zhang, Y., Weldon, W. C., Oberste, M. S., Gunasena, S., & Sutter, R. W. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy389 · Cited by 25
“Indeed, we found lower than anticipated excretion of PV2 in the no IPV study arm, suggesting secondary transmission of PV2 [32].”
Schoub, B. D. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.056 · Cited by 23
Inductive/Effector Mechanisms for Humoral Immunity at Mucosal Sites
Wright, P. F. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00954.x · Cited by 24
Andreasen, L. V., Hansen, L. B., Andersen, P. L., Agger, E. M., & Dietrich, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.011 · Cited by 22
Rodriguez, F. V., Lopez, N. B., & Choonara, I. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.131615 · Cited by 21
Immunogenicity of intramuscular fractional dose of inactivated poliovirus vaccine
Resik, S., Mach, O., Tejeda, A., Jeyaseelan, V., Fonseca, M. C., Dı́az, M., Alemañy, N., Hung, L. H., Alemán, Y., Mesa, I., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz323 · Cited by 21
A quantitative survey of the literature on poliovirus infection and immunity
Behrend, M. R., Hu, H., Nigmatulina, K. R., & Eckhoff, P. A. (2013) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.09.005 · Cited by 25
Pírez, C., Olivera, I., Diabarboure, H., Montano, A., Barañano, R., Badía, F., & Bonnet, M.-C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.042 · Cited by 19
Tebbens, R. J. D., & Thompson, K. M. (2017) · MDM Policy & Practice · doi:10.1177/2381468317697002 · Cited by 20
He, H., Wang, Y., Deng, X., Yue, C., Tang, X., Li, Y., Liu, Y., Yin, Z., Zhang, G., Chen, Z., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30738-8 · Cited by 18
Mucosal immunity to poliovirus
Ogra, P. L. O., Okayasu, H., Czerkinsky, C. C., & Sutter, R. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.106 · Cited by 19
Switching from OPV to IPV: are we behind the schedule in Latin America?
Peraza, D. S., Avila-Aguero, M. L., & Morice, A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.39 · Cited by 17
Polio endgame: Lessons for the global rotavirus vaccination program
Jiang, B., Patel, M. M., & Glass, R. I. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.023 · Cited by 19
Tang, G., Yin, W., Cao, Y., Tan, L., Wu, S.-Y., Cao, Y., Fu, X., Yan, J., & Jiang, X. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1489188 · Cited by 15
Bandyopadhyay, A. S., Asturias, E. J., O’Ryan, M., Oberste, M. S., Weldon, W. C., Clemens, R. L., Rüttimann, R. W., Modlin, J. F., & Gast, C. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.006 · Cited by 13
Tebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3074-0 · Cited by 12
On the training of young doctors in China.
Wáng, Y. X. J. (2015) · PubMed · doi:10.3978/j.issn.2223-4292.2014.12.01 · Cited by 10
“In 2007, the Cuba IPV Study Collaborative Group reported that inactivated poliovirus vaccine was effective in vaccinating children in tropical conditions (23).”
BackgroundGiri, S., Kumar, N., Dhanapal, P., Venkatesan, J., Kasirajan, A., Iturriza‐Gómara, M., John, J. K., Abraham, A. M., Grassly, N. C., & Kang, G. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix687 · Cited by 9
“This same relationship is not observed among individuals who received inactivated poliovirus vaccine, which induces limited mucosal protection despite high titers of serum neutralizing antibodies [15].”
BackgroundCirculating vaccine derived poliovirus and the polio eradication endgame.
Davis, R., & Wright, P. F. (2012) · PubMed Central · Cited by 9
Monovalent Oral Poliovirus Vaccines — A Good Tool but Not a Total Solution
Ehrenfeld, E., & Chumakov, K. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806810 · Cited by 9
Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine
Sutter, R. W. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix557 · Cited by 10
Zaman, K., Kovacs, S., VanderEnde, K. E., Aziz, A. B., Yunus, M., Khan, S., Snider, C. J., An, Q., Estívariz, C. F., Oberste, M. S., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.065 · Cited by 8
Jaiswal, N., Singh, S., Agarwal, A. K., Chauhan, A., Thumburu, K. K., Kaur, H., & Singh, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011780.pub2 · Cited by 8
“We excluded 13 studies that did not meet our inclusion criteria aEer full-text screening (Aaby 2007; Bakker 2011; Bégué 1998; Choudhury 2011; Cuba IPV Study Group 2007; Grassly 2014; Klein 2012; Li 2016; NCT00871000; Nirmal 1998; O’Ryan 2015; Verdijk 2013; WHO Collaborative Study 1996).”
BackgroundMethodInfluentialInactivated Polio Vaccine: its proposed role in the final stages of polio eradication
Davis, R., & Biellik, R. (2013) · Pan African Medical Journal · doi:10.11604/pamj.2013.14.102.2580 · Cited by 8
Habib, M. A., Soofi, S. B., Hussain, I., Ahmed, I., Hussain, Z., Tahir, R., Anwar, S., Cousens, S., & Bhutta, Z. A. (2023) · Vaccines · doi:10.3390/vaccines11091444 · Cited by 5
“Despite receiving zero, two, or three prior IPV doses in Cuba, over 90% of infants shed some form of poliovirus following the tOPV challenge [48].”
BackgroundTagbo, B. N., Verma, H., Mahmud, Z. M., Ernest, K., Nnani, R. O., Chukwubike, C. M., Craig, K., Hamisu, A. W., Weldon, W. C., Oberste, S. M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa726 · Cited by 5
Goodbye switch and Imminent Polio Victory
Jog, P. P. (2016) · Indian Pediatrics · doi:10.1007/s13312-016-0837-9 · Cited by 4
Romero, J. R., & Modlin, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00173-9 · Cited by 7
Cuba’s Scientific Contributions to Global Polio Eradication
Resik, S., Mach, O., Tejeda, A., Galindo, M. A., & Sutter, R. W. (2018) · MEDICC Review · doi:10.37757/mr2018.v20.n2.9 · Cited by 3
Sharma, A. K., Verma, H., Estívariz, C. F., Bajracharaya, L., Rai, G., Shah, G., Sherchand, J. B., Jones, K. A. V., Mainou, B. A., Chavan, S. S., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00215-x · Cited by 4
Inactivated polio vaccine and global polio eradication
Modlin, J. F. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70312-7 · Cited by 3
Poliovirus Vaccine—Inactivated
Vidor, E. J., & Modlin, J. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00049-9 · Cited by 5
Estívariz, C. F., Burns, C. C., & Macklin, G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00050-5 · Cited by 4
Modlin, J. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00171-5 · Cited by 1
Protective efficacy of a monovalent oral type 1 poliovirus vaccine – Authors' reply
Grassly, N. C., Wenger, J. D., Bahl, S. K., Sutter, R. W., & Aylward, R. B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61077-0 · Cited by 1
Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity
Mei, R., Kwok, S. L. L., Lau, E. H. Y., Lo, T. H. K., Wu, J. T. K., Lin, L. K., & Leung, K. S. M. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.02.026 · Cited by 1
Caeymaex, L. (2012) · Revue de médecine périnatale · doi:10.1007/s12611-012-0213-5
Renaissance of an “old” vaccine
Sutter, R. W., & Kew, O. M. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00526-5
Inactivated Poliovirus Vaccine Immunogenic in Cuban Infants
Wilson, M. E. (2007) · Journal watch · doi:10.1056/id200704110000001
Metadata
- Authors
- The Cuba IPV Study Collaborative Group
- Corresponding author
- The Cuba IPV Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1536-1544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2335890187
- Cited by
- 90
- References
- 22
- Citations by year
- 2024: 1 · 2023: 7 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 3 · 2015: 11 · 2014: 4 · 2013: 7 · 2012: 9
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, infants, poliovirus type 2, Cuba, tropical developing countries, vaccine adverse events, hypotonia, viral shedding in stool, polio eradication
- MeSH terms
- Antibodies, Viral, Cuba, Feces, Humans, Infant, Infant, Newborn, Poliomyelitis, Poliovirus Vaccine, Inactivated, Polysaccharides, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Bacterial Capsules, Vaccines, Combined, Poliovirus, Haemophilus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.